Health care is a vulnerabilityfor the president entering his re-election, and his budget proposalreleased Monday projects billions in unspecified drug-costsavings.

(Bloomberg) –President Donald Trump is considering executiveaction to cut drug prices ahead of the 2020 election, officialsfamiliar with the matter say, as he enters his re-election seekingto rebut Democratic criticism that his policies have hurt U.S.health care.

If he proceeds, Trump would force drug companies to accept lowerpayments from Medicare for treatments administered in doctors'offices, such as Bristol-Myers Squibb Co.'s immune-boosting Opdivofor cancer and Regeneron Pharmaceuticals Inc.'s Eylea for eyeconditions. The rule would apply to certain drugs bought by the"Part B" section of Medicare, the program for the elderly anddisabled.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Health Care Reform
Cost-Containment